| Autor: |
Ilaria Sauzullo, Fabio Mengoni, Raffaella Rossi, Miriam Lichtner, Maria Cecilia Rizza, Fernanda Chiarini, Claudio Maria Mastroianni, Vincenzo Vullo |
| Jazyk: |
English<br />Italian |
| Rok vydání: |
2008 |
| Předmět: |
|
| Zdroj: |
Microbiologia Medica, Vol 23, Iss 3 (2008) |
| Druh dokumentu: |
article |
| ISSN: |
2280-6423 |
| DOI: |
10.4081/mm.2008.2575 |
| Popis: |
Introduction: The identification and characterization of two M. tuberculosis-specific antigens (ESAT-6 and CFP- 10) has led to the development of a whole blood new generation of M. tuberculosis specific diagnostic tests, that have several advantages over tuberculin skin test (TST), in terms of higher specificity, better correlation with surrogate measures of exposure to M. tuberculosis in low-incidence setting, and less cross-reactivity with M. bovis (BCG) vaccine and environmental mycobacteria.The role of these new tests in evaluating post-therapy tuberculosis eradication has not been investigated yet. Aim of this longitudinal study was to determinate changes of response to M. tuberculosis-specific antigens in patients during the standard tuberculosis treatment and to investigate the in vitro effects of tuberculosis drugs on the IFN-γ release. Methods: 23 individuals with active tuberculosis were enrolled and followed over time.They were tested with QuantiFERON TB-Gold (QFT-Gold) at four time points: at diagnosis (t0), after 3 and 6 months of treatment (t1- t2) and at the end of the specific treatment (t3). Results: At baseline all patients were positive by QFT-Gold.At second time-point 17 out of 23 (74%) were positive, at third time-point 11 of 23 (47%) were positive, at treatment completion 3/23 (13%) were positive.The conversion to negative response to M. tuberculosis-specific antigens was found in 87% patients analyzed after successful therapy. Longitudinal QFT-Gold testing shown a significant decrease (p |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
